Concepts and challenges in quantitative pharmacology and model-based drug development.
about
Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and SimulationsIntegrating Multiscale Modeling with Drug Effects for Cancer TreatmentRevisiting the Middle Molecule Hypothesis of Uremic Toxicity: A Systematic Review of Beta 2 Microglobulin Population Kinetics and Large Scale Modeling of Hemodialysis Trials In SilicoAgent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivityIntegrating experimentation and quantitative modeling to enhance discovery of Beta amyloid lowering therapeutics for Alzheimer's disease.White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation.Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBInteractive Pharmacometric Applications Using R and the Shiny PackageModeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenTarget-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice.Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.Reversible exacerbation of obstructive sleep apnea by α1-adrenergic blockade with tamsulosin: A case report.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.Next-generation model-based drug discovery and development: quantitative and systems pharmacology.Improving productivity with model-based drug development: an enterprise perspective.Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development.The current role of model-based drug development.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.At the bench: the key role of PK-PD modelling in enabling the early discovery of biologic therapiesModel-based clinical drug development in the past, present and future: a commentary.Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration.Approaches to in vitro tissue regeneration with application for human disease modeling and drug development.Dashboard systems: implementing pharmacometrics from bench to bedside.Tools for predicting the PK/PD of therapeutic proteins.Drug Development of Therapeutic Monoclonal Antibodies.Quantitative Evaluation and Prediction of Drug Effects and Toxicological Risk Using Mechanistic Multiscale Models.Design, conduct, analysis, and interpretation of clinical studies in patients with impaired kidney function.Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success.Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa.Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development.Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design.Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development.
P2860
Q26739743-C4A0CDF1-85FC-4B73-A84E-B542FF16E9A3Q26770510-2AA0B0EE-D822-4478-924C-527716BD334BQ27009538-D347F38A-8865-4CC5-BD5D-DCE9CCF07C53Q27028010-53D1126C-A739-420E-87AB-D297591DBE8BQ30422271-0DD6DC4F-6DBD-451A-A2B2-62A0E748ED50Q30540355-FCEE931B-4A38-4B6B-BB20-E7130597BA26Q33524423-5D68B6E4-C20A-4512-A273-3035C065E903Q33824750-67BDB745-7D2A-4267-A923-93F5C2E48EEFQ34099766-ACC80F9D-D4A0-4BA8-9F18-D353D3C73F0FQ34591451-15F6C878-BD5F-4C52-A5FD-F0771F51CF14Q35382855-545C3599-075D-4B1A-B0CD-C9B7C2CA284EQ35768386-18EFFAAD-888F-4355-AD9E-12C06E62F927Q36322918-7DA5B92E-E676-4AC9-B2EE-4C7A2EE3258BQ36502390-53F0D9BD-97A0-4204-8594-7B7126F98A1BQ37259653-A640C603-E1FB-4481-9E4E-932C7108E78DQ37363689-C692204F-788C-4BC5-81F8-FA56E3DE73ABQ37521422-1EEFF578-373E-4191-8364-77CD7B3A4954Q37763515-3696A264-B1F6-40E1-8775-28FDAF54FD36Q37769100-12FA0805-5AA5-45FB-BBB6-347B324C0DFDQ38013289-58F0EB42-39FD-48A8-8B36-9ADACC172DF9Q38028538-E6BDCBD2-E0CE-4E5E-A4DA-59A1E32BD96BQ38110433-8E987E23-54F0-418B-A985-0F281F228FF5Q38130330-4B2B6EF1-5047-4A07-A67F-DF748DE3EECEQ38188035-4A81F56C-6352-426C-9C09-298E5C77133DQ38194107-F323AB1A-A1AF-4AA1-AE6F-81E27D54ECA6Q38209078-47CC7C40-6639-4615-AF68-D0723BB9B161Q38221759-09293842-6051-44C1-BCA8-545AE91BE05AQ38455786-7C925772-6A1F-4321-A5D2-350D7D08C736Q38876360-3A1F5471-80D8-4D0A-917C-EB08896A945CQ38915439-52FC7516-239A-43A6-AAEA-7718E4C9E7B2Q39664155-F858B0F7-CD41-4819-8465-5117AE05E8ECQ39828343-ABF8D4B0-9D12-4DAF-84B2-E0D9B7EDE915Q39828349-C5D3849E-A246-4470-9505-8BA74954C736Q42249532-47D4928C-3840-42DC-96E8-0EC87236B31CQ42945852-86542A90-2436-4796-A1BF-EFADBFBEC9EBQ43772541-5DDDCA12-BE6D-4B2C-8153-445EB17EEEA2Q43985737-F72BE5F5-AB1C-49D7-BC5B-D196DB7AFD2AQ47877945-FB68A178-9A8E-4764-A65C-50CEBE2803EEQ50127370-F9239424-5BAB-4F62-B7F3-BC2C15F9F757Q51570078-AC937011-CE6B-4342-869C-340536E162B5
P2860
Concepts and challenges in quantitative pharmacology and model-based drug development.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Concepts and challenges in quantitative pharmacology and model-based drug development.
@ast
Concepts and challenges in quantitative pharmacology and model-based drug development.
@en
Concepts and challenges in quantitative pharmacology and model-based drug development.
@nl
type
label
Concepts and challenges in quantitative pharmacology and model-based drug development.
@ast
Concepts and challenges in quantitative pharmacology and model-based drug development.
@en
Concepts and challenges in quantitative pharmacology and model-based drug development.
@nl
prefLabel
Concepts and challenges in quantitative pharmacology and model-based drug development.
@ast
Concepts and challenges in quantitative pharmacology and model-based drug development.
@en
Concepts and challenges in quantitative pharmacology and model-based drug development.
@nl
P2093
P2860
P1433
P1476
Concepts and challenges in quantitative pharmacology and model-based drug development.
@en
P2093
Bernd Meibohm
Liping Zhang
Marc Pfister
P2860
P2888
P304
P356
10.1208/S12248-008-9062-3
P407
P577
2008-11-12T00:00:00Z
P5875
P6179
1033487351